Edwards Lifesciences logged a -30.2% change during today's afternoon session, and is now trading at a price of $60.65 per share.
Edwards Lifesciences returned gains of 5.2% last year, with its stock price reaching a high of $96.12 and a low of $60.52. Over the same period, the stock underperformed the S&P 500 index by -14.4%. The company's 50-day average price was $88.99. Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. Based in Irvine, CA, the Large-Cap Health Care company has 19,800 full time employees. Edwards Lifesciences has not offered a dividend during the last year.
Wider Gross Margins Than the Industry Average of 42.5%:
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue (M) | $3,723 | $4,348 | $4,386 | $5,232 | $5,382 | $6,005 |
| Gross Margins | 75% | 74% | 75% | 76% | 80% | 77% |
| Net Margins | 19% | 24% | 19% | 28% | 28% | 23% |
| Net Income (M) | $722 | $1,047 | $823 | $1,503 | $1,522 | $1,402 |
| Net Interest Expense (M) | $30 | $21 | $16 | $18 | $19 | $18 |
| Depreciation & Amort. (M) | $77 | $89 | $107 | $135 | $140 | $145 |
| Diluted Shares (M) | 641 | 637 | 632 | 631 | 624 | 609 |
| Earnings Per Share | $1.13 | $1.64 | $1.3 | $2.38 | $2.44 | $2.3 |
| EPS Growth | n/a | 45.13% | -20.73% | 83.08% | 2.52% | -5.74% |
| Avg. Price | $47.43 | $66.6 | $76.09 | $102.64 | $107.47 | $61.52 |
| P/E Ratio | 41.24 | 39.64 | 58.08 | 42.59 | 44.05 | 26.63 |
| Free Cash Flow (M) | $688 | $928 | $647 | $1,406 | $974 | $643 |
| CAPEX (M) | $239 | $254 | $407 | $326 | $245 | $253 |
| EV / EBITDA | 36.05 | 33.11 | 46.92 | 34.98 | 35.38 | 21.96 |
| Total Debt (M) | $594 | $594 | $595 | $596 | $596 | $597 |
| Net Debt / EBITDA | -0.15 | -0.47 | -0.59 | -0.15 | -0.09 | -0.33 |
| Current Ratio | 2.61 | 3.31 | 3.46 | 3.08 | 3.03 | 3.38 |
Edwards Lifesciences benefits from an excellent current ratio of 3.38, growing revenues and a flat capital expenditure trend, and wider gross margins than its peer group. The company's financial statements show a strong EPS growth trend and healthy leverage levels. Furthermore, Edwards Lifesciences has positive cash flows.
an Increase in Expected Earnings Improves Its Value Outlook but Trades Above Its Graham Number:
Edwards Lifesciences has a trailing twelve month P/E ratio of 37.2, compared to an average of 27.61 for the Health Care sector. Based on its EPS guidance of $3.1, the company has a forward P/E ratio of 28.7. Edwards Lifesciences's PEG ratio is 3.13 on the basis of the 11.9% weighted average of the company and the broader market's EPS compound average growth rates. This suggests that the company's shares are overvalued. Furthermore, Edwards Lifesciences is likely overvalued compared to the book value of its equity, since its P/B ratio of 4.91 is higher than the sector average of 3.69. The company's shares are currently trading 155.3% below their Graham number. Ultimately, Edwards Lifesciences's strong cash flows, decent earnings multiple, and healthy debt levels factor towards it being fairly valued, its elevated P/B ratio notwithstanding.
Edwards Lifesciences Has an Analyst Consensus of Strong Upside Potential:
The 26 analysts following Edwards Lifesciences have set target prices ranging from $70.0 to $110.0 per share, for an average of $96.75 with a buy rating. The company is trading -37.3% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Edwards Lifesciences has a very low short interest because 1.3% of the company's shares are sold short. Institutions own 84.6% of the company's shares, and the insider ownership rate stands at 0.89%, suggesting a small amount of insider investors. The largest shareholder is Vanguard Group Inc, whose 9% stake in the company is worth $3,212,290,576.
